MDT-AP-0539
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 36
- age_years
- 3
- sex
- F
- new_clusters
- S2
- umap1_2d
- -0.736681166
- umap2_2d
- -9.520357036
- umap1_3d
- -3.561207574
- umap2_3d
- -1.380684595
- umap3_3d
- 5.424531929
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- INTERFERON_ALPHA_RESPONSE+0.450
- G2M_CHECKPOINT+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- MYC_TARGETS_V1+0.360
- ALLOGRAFT_REJECTION+0.330
- INTERFERON_GAMMA_RESPONSE+0.330
- COAGULATION+0.310
- MYC_TARGETS_V2+0.310
- IL6_JAK_STAT3_SIGNALING+0.270
Top 10 suppressed
- HEME_METABOLISM-0.300
- TGF_BETA_SIGNALING-0.190
- PROTEIN_SECRETION-0.160
- ADIPOGENESIS-0.130
- OXIDATIVE_PHOSPHORYLATION-0.120
- FATTY_ACID_METABOLISM-0.110
- PI3K_AKT_MTOR_SIGNALING-0.090
- TNFA_SIGNALING_VIA_NFKB-0.080
- XENOBIOTIC_METABOLISM-0.040
- UV_RESPONSE_UP-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1133 | Med | Medulloblastoma | 0.867 |
| 2 | MDT-AP-2102 | Med | Medulloblastoma | 0.835 |
| 3 | MDT-AP-1196 | Med | Medulloblastoma | 0.833 |
| 4 | TCGA-BH-A0B3-01A-11R-A056-07 | — | E | 0.819 |
| 5 | MDT-AP-3067 | Med | Medulloblastoma | 0.819 |
| 6 | TCGA-22-5489-01A-01R-1635-07 | — | cohortSQ1 | 0.816 |
| 7 | MDT-AP-1106 | Med | Medulloblastoma | 0.816 |
| 8 | F5EB77B4-61AD-40EC-B5B0-44D2D5AD66D7 | — | — | 0.808 |
| 9 | MDT-AP-0732 | Med | Medulloblastoma | 0.802 |
| 10 | 02fde1b1-c95c-4d8f-b57b-355b55072108 | — | — | 0.801 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.360 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.310 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.190 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.160 | Inavolisib | — uncovered |